1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …

Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity
and mortality. VTE prevention and treatment are more complex in patients with cancer. The …

Numerous types of cancer have been shown to be associated with either ischemic or
hemorrhagic stroke. In this review, the epidemiology and pathophysiology of stroke in …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …

Patients with active cancer are at an increased risk of arterial and venous thromboembolism
(VTE) and bleeding events. Historically, in patients with cancer, low molecular weight …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging
due to complications—including bleeding and potential drug–drug interactions with …